Laura Joyce Wozniak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Laura Joyce Wozniak has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
Douglas G. Farmer
Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
9 shared publicationsRobert S. Venick
Pediatric Gastroenterology, Hepatology, and Nutrition, David Geffen School of Medicine at UCLA
9 shared publicationsSue V. McDiarmid
Pediatric Gastroenterology, Hepatology, and Nutrition, David Geffen School of Medicine at UCLA
9 shared publicationsRonald W. Busuttil
Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
7 shared publicationsElizabeth A. Marcus
Division of Pediatric Gastroenterology, Hepatology and Nutrition Los Angeles CA
6 shared publicationsJorge H. Vargas
Division of Pediatric Gastroenterology Hepatology, and Nutrition David Geffen School of Medicine at UCLA Los Angeles California USA
6 shared publications
Latest Publications
- 25 June 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (7) , e70382
Dupilumab Is Safe and Efficacious for Treatment of Eosinophilic Esophagitis and Atopic Dermatitis in Pediatric Liver Transplant Recipients: A Case Series
Background: Transplant‐acquired atopy and allergic disorders, including atopic dermatitis and eosinophilic gastrointestinal disorders, are known complications of organ transplantation. They have been noted to be more prevalent following liver transplantation than other solid organ transplantations. The pathophysiology is unknown; however, tacrolimus immunosuppression has been hypothesized to play a role via T helper 2 cell predominance, leading to increased interleukin‐4 and interleukin‐13 expression. Dupilumab, a monoclonal antibody that downregulates interleukin‐4, interleukin‐13, and the T helper 2 cell pathway, is effective for atopic dermatitis and eosinophilic esophagitis, though there is a paucity of data regarding its use and safety in pediatric liver transplant recipients. Methods and Results: We report a series of cases of pediatric liver transplant recipients from a single center who developed severe atopic dermatitis or eosinophilic esophagitis that was refractory to routine treatments and immunosuppression changes. These atopic conditions also severely affected their quality of life. After initiation of dupilumab, the patients had improvement in both their atopic conditions and quality of life. Patients who did not have evidence of graft dysfunction or rejection prior to initiation of dupilumab maintained normal biochemical graft function. Patients who had rejection prior to starting dupilumab did not develop acute worsening of their graft function or rejection. Conclusions: In this case series, dupilumab was seen to be effective for pediatric liver transplant recipients who developed atopic dermatitis or eosinophilic esophagitis that was refractory to routine treatment and immunosuppression changes. While receiving dupilumab, these patients did not develop worsening graft function or rejection.
- 25 June 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (7) , e70382
Dupilumab Is Safe and Efficacious for Treatment of Eosinophilic Esophagitis and Atopic Dermatitis in Pediatric Liver Transplant Recipients: A Case Series
Background: Transplant‐acquired atopy and allergic disorders, including atopic dermatitis and eosinophilic gastrointestinal disorders, are known complications of organ transplantation. They have been noted to be more prevalent following liver transplantation than other solid organ transplantations. The pathophysiology is unknown; however, tacrolimus immunosuppression has been hypothesized to play a role via T helper 2 cell predominance, leading to increased interleukin‐4 and interleukin‐13 expression. Dupilumab, a monoclonal antibody that downregulates interleukin‐4, interleukin‐13, and the T helper 2 cell pathway, is effective for atopic dermatitis and eosinophilic esophagitis, though there is a paucity of data regarding its use and safety in pediatric liver transplant recipients. Methods and Results: We report a series of cases of pediatric liver transplant recipients from a single center who developed severe atopic dermatitis or eosinophilic esophagitis that was refractory to routine treatments and immunosuppression changes. These atopic conditions also severely affected their quality of life. After initiation of dupilumab, the patients had improvement in both their atopic conditions and quality of life. Patients who did not have evidence of graft dysfunction or rejection prior to initiation of dupilumab maintained normal biochemical graft function. Patients who had rejection prior to starting dupilumab did not develop acute worsening of their graft function or rejection. Conclusions: In this case series, dupilumab was seen to be effective for pediatric liver transplant recipients who developed atopic dermatitis or eosinophilic esophagitis that was refractory to routine treatment and immunosuppression changes. While receiving dupilumab, these patients did not develop worsening graft function or rejection.
- 25 February 2020
- Published by Wolters Kluwer Health in Transplantation
- Vol. 104 (12) , 2547-2556
Angiotensin II Type-1 Receptor Antibodies Are Associated With Active Allograft Dysfunction Following Pediatric Liver Transplantation
Background.: Angiotensin II type-1 receptor (AT1R) antibodies have been associated with rejection and allograft loss in solid organ transplantation and may act synergistically with HLA donor-specific antibodies (DSA). Our aims were to assess the prevalence of AT1R antibodies and determine if they were associated with allograft dysfunction in pediatric liver transplant recipients. Methods.: We performed a retrospective, cross-sectional study of HLA DSA and AT1R antibodies in 2 cohorts of pediatric liver transplant recipients: a stable control cohort with normal allograft function (n = 70) who consented to have serum samples collected for research purposes during a routine clinic visit and a cohort with active allograft dysfunction (n = 9) whose serum samples were collected as part of clinical care. Results.: AT1R antibodies >17 U/mL were detected in 29% of stable control patients and 89% of patients with active allograft dysfunction (P = 0.001). In stable control patients, AT1R antibodies were associated with younger age at transplant (P = 0.010), younger age at time of sample collection (P < 0.001), shorter interval since transplant (P = 0.090), and presence of HLA DSA (P = 0.003). AT1R antibodies in stable control patients were not associated with rejection or allograft loss. However, AT1R antibodies combined with HLA DSA in patients with active allograft dysfunction were associated with rejection and allograft loss. Conclusions.: Our results suggest that AT1R antibodies are more common in patients with active allograft dysfunction and may be a risk factor for worse outcomes. Further research is needed to longitudinally assess the clinical impact of HLA DSA and AT1R antibodies.
- 25 February 2020
- Published by Wolters Kluwer Health in Transplantation
- Vol. 104 (12) , 2547-2556
Angiotensin II Type-1 Receptor Antibodies Are Associated With Active Allograft Dysfunction Following Pediatric Liver Transplantation
Background.: Angiotensin II type-1 receptor (AT1R) antibodies have been associated with rejection and allograft loss in solid organ transplantation and may act synergistically with HLA donor-specific antibodies (DSA). Our aims were to assess the prevalence of AT1R antibodies and determine if they were associated with allograft dysfunction in pediatric liver transplant recipients. Methods.: We performed a retrospective, cross-sectional study of HLA DSA and AT1R antibodies in 2 cohorts of pediatric liver transplant recipients: a stable control cohort with normal allograft function (n = 70) who consented to have serum samples collected for research purposes during a routine clinic visit and a cohort with active allograft dysfunction (n = 9) whose serum samples were collected as part of clinical care. Results.: AT1R antibodies >17 U/mL were detected in 29% of stable control patients and 89% of patients with active allograft dysfunction (P = 0.001). In stable control patients, AT1R antibodies were associated with younger age at transplant (P = 0.010), younger age at time of sample collection (P < 0.001), shorter interval since transplant (P = 0.090), and presence of HLA DSA (P = 0.003). AT1R antibodies in stable control patients were not associated with rejection or allograft loss. However, AT1R antibodies combined with HLA DSA in patients with active allograft dysfunction were associated with rejection and allograft loss. Conclusions.: Our results suggest that AT1R antibodies are more common in patients with active allograft dysfunction and may be a risk factor for worse outcomes. Further research is needed to longitudinally assess the clinical impact of HLA DSA and AT1R antibodies.
- 1 May 2019
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 68 (5) , 689-694
Esophageal IgG4
Objective: Recent studies show increased serum and esophageal IgG4 in patients with eosinophilic esophagitis (EoE), suggesting a possible IgG4‐involved process. The role of IgG4 in pediatric EoE has not been extensively investigated. Our aim was to analyze IgG4 in esophageal tissue in children in parallel to that in adults with EoE.Methods: In a retrospective institutional review board–approved study, we performed immunohistochemical staining of IgG4 in esophageal biopsy specimens from 39 subjects: children with EoE (n = 16), adults with EoE (n = 15), children with reflux esophagitis (n = 4), and pediatric controls (n = 4). We assessed the relationships between IgG4 staining and clinical, endoscopic, and histopathologic characteristics.Results: Patients with EoE were significantly more likely to stain positively for IgG4 than children with reflux esophagitis or controls (P = 0.015). Fifteen of 31 (48%) EoE cases stained positively for IgG4. None of the reflux esophagitis or control cases stained positively. IgG4 staining had 48% sensitivity and 100% specificity for EoE. There was a trend toward IgG4 staining being associated with foreign body/food impaction (P = 0.153). There was a strong association between distal IgG4 staining and basal zone hyperplasia (P = 0.003).Conclusions: Our study suggests IgG4 is not a consistent finding of EoE at disease diagnosis. Although IgG4 staining was specific for EoE, it had a poor sensitivity with positive staining in only 48% of EoE patients. Further studies are warranted to fully elucidate the role of IgG4 in EoE.
- 1 May 2019
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 68 (5) , 689-694
Esophageal IgG4
Objective: Recent studies show increased serum and esophageal IgG4 in patients with eosinophilic esophagitis (EoE), suggesting a possible IgG4‐involved process. The role of IgG4 in pediatric EoE has not been extensively investigated. Our aim was to analyze IgG4 in esophageal tissue in children in parallel to that in adults with EoE.Methods: In a retrospective institutional review board–approved study, we performed immunohistochemical staining of IgG4 in esophageal biopsy specimens from 39 subjects: children with EoE (n = 16), adults with EoE (n = 15), children with reflux esophagitis (n = 4), and pediatric controls (n = 4). We assessed the relationships between IgG4 staining and clinical, endoscopic, and histopathologic characteristics.Results: Patients with EoE were significantly more likely to stain positively for IgG4 than children with reflux esophagitis or controls (P = 0.015). Fifteen of 31 (48%) EoE cases stained positively for IgG4. None of the reflux esophagitis or control cases stained positively. IgG4 staining had 48% sensitivity and 100% specificity for EoE. There was a trend toward IgG4 staining being associated with foreign body/food impaction (P = 0.153). There was a strong association between distal IgG4 staining and basal zone hyperplasia (P = 0.003).Conclusions: Our study suggests IgG4 is not a consistent finding of EoE at disease diagnosis. Although IgG4 staining was specific for EoE, it had a poor sensitivity with positive staining in only 48% of EoE patients. Further studies are warranted to fully elucidate the role of IgG4 in EoE.
- 11 June 2018
- Published by Wiley in Clinical Transplantation
- Vol. 32 (8) , e13313
Clinical characteristics and outcomes of PTLD following intestinal transplantation
Post‐transplant lymphoproliferative disease (PTLD) has the highest incidence following intestinal transplantation (ITx). Our center has seen a recent increase in PTLD. Our aim was to review a single‐center PTLD experience with a focus on clinical characteristics and outcomes. We completed a retrospective review of biopsy‐proven PTLD cases using a prospectively maintained database of 115 ITx recipients transplanted between 1991 and 2014. Nineteen (17%) ITx recipients developed 25 PTLD cases during a median follow‐up time of 6.4 (1.6‐14.6) years. The incidence of early PTLD was 6% (n = 7). There was a trend toward increased risk of PTLD in children compared with adults (P = .11) and a significantly increased risk of PTLD in re‐ITx compared with primary ITx recipients (P = .03). Most PTLD cases were diagnosed between 2010 and 2014 (n = 14). All early PTLD cases were EBV+ on in situ hybridization. Overall graft and patient survival are 68% and 74%, respectively. Second episodes of PTLD were diagnosed in 43% of surviving pediatric patients. Our program has a low incidence of early PTLD with overall excellent graft and patient survival following diagnosis. However, we have also seen a rising incidence of late PTLD. The cause of the increase is unknown as no major changes in immunosuppression protocols have occurred since 1999.
- 11 June 2018
- Published by Wiley in Clinical Transplantation
- Vol. 32 (8) , e13313
Clinical characteristics and outcomes of PTLD following intestinal transplantation
Post‐transplant lymphoproliferative disease (PTLD) has the highest incidence following intestinal transplantation (ITx). Our center has seen a recent increase in PTLD. Our aim was to review a single‐center PTLD experience with a focus on clinical characteristics and outcomes. We completed a retrospective review of biopsy‐proven PTLD cases using a prospectively maintained database of 115 ITx recipients transplanted between 1991 and 2014. Nineteen (17%) ITx recipients developed 25 PTLD cases during a median follow‐up time of 6.4 (1.6‐14.6) years. The incidence of early PTLD was 6% (n = 7). There was a trend toward increased risk of PTLD in children compared with adults (P = .11) and a significantly increased risk of PTLD in re‐ITx compared with primary ITx recipients (P = .03). Most PTLD cases were diagnosed between 2010 and 2014 (n = 14). All early PTLD cases were EBV+ on in situ hybridization. Overall graft and patient survival are 68% and 74%, respectively. Second episodes of PTLD were diagnosed in 43% of surviving pediatric patients. Our program has a low incidence of early PTLD with overall excellent graft and patient survival following diagnosis. However, we have also seen a rising incidence of late PTLD. The cause of the increase is unknown as no major changes in immunosuppression protocols have occurred since 1999.
- 15 February 2018
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 42 (5) , 942-948
Epidemiology and Risk Factors for Outpatient‐Acquired Catheter‐Related Bloodstream Infections in Children Receiving Home Parenteral Nutrition
Background: Few studies have examined the epidemiology and risk factors for the development of outpatient‐acquired catheter‐related bloodstream infections (CRBSIs) in children receiving home parenteral nutrition. This study aimed to (1) characterize the incidence, clinical presentation, and epidemiology of CRBSIs and (2) identify risk factors for CRBSIs in children receiving home parenteral nutrition.Methods: A longitudinal database approved by our Institutional Review Board was created to prospectively track CRBSIs in the UCLA pediatric population from January to December 2012. Eligible patients included those < 18 years old receiving home parenteral nutrition.Results: Thirty of 60 patients (50%) were diagnosed with 66 CRBSIs, for an overall CRBSI rate of 3.6 per 1000 catheter days. Of the CRBSIs, 73% were due to single microorganisms and 27% were polymicrobial. There was a significant difference in median (range) time for blood cultures to turn positive depending on type of CRBSIs (p = 0.03), with polymicrobial infections detected at 13.4 (8.7–24.3) hours, gram‐negative infections at 16.5 (9–30.8) hours, and gram‐positive infections at 18.9 (8.4–37.1) hours. The most common presenting symptom was fever (82%), followed by gastrointestinal symptoms (42%) and chills (29%). The only significant multivariate risk factor for CRBSIs was presence of a feeding tube (2.3‐fold increase in CRBSI risk, p = 0.04).Discussion: Outpatient‐acquired CRBSIs are common in children receiving home parenteral nutrition. CRBSIs typically present with fever, but are also associated with gastrointestinal and/or respiratory symptoms. The presence of feeding tubes may predispose children on home parenteral nutrition to developing CRBSIs.
- 15 February 2018
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 42 (5) , 942-948
Epidemiology and Risk Factors for Outpatient‐Acquired Catheter‐Related Bloodstream Infections in Children Receiving Home Parenteral Nutrition
Background: Few studies have examined the epidemiology and risk factors for the development of outpatient‐acquired catheter‐related bloodstream infections (CRBSIs) in children receiving home parenteral nutrition. This study aimed to (1) characterize the incidence, clinical presentation, and epidemiology of CRBSIs and (2) identify risk factors for CRBSIs in children receiving home parenteral nutrition.Methods: A longitudinal database approved by our Institutional Review Board was created to prospectively track CRBSIs in the UCLA pediatric population from January to December 2012. Eligible patients included those < 18 years old receiving home parenteral nutrition.Results: Thirty of 60 patients (50%) were diagnosed with 66 CRBSIs, for an overall CRBSI rate of 3.6 per 1000 catheter days. Of the CRBSIs, 73% were due to single microorganisms and 27% were polymicrobial. There was a significant difference in median (range) time for blood cultures to turn positive depending on type of CRBSIs (p = 0.03), with polymicrobial infections detected at 13.4 (8.7–24.3) hours, gram‐negative infections at 16.5 (9–30.8) hours, and gram‐positive infections at 18.9 (8.4–37.1) hours. The most common presenting symptom was fever (82%), followed by gastrointestinal symptoms (42%) and chills (29%). The only significant multivariate risk factor for CRBSIs was presence of a feeding tube (2.3‐fold increase in CRBSI risk, p = 0.04).Discussion: Outpatient‐acquired CRBSIs are common in children receiving home parenteral nutrition. CRBSIs typically present with fever, but are also associated with gastrointestinal and/or respiratory symptoms. The presence of feeding tubes may predispose children on home parenteral nutrition to developing CRBSIs.
- 1 April 2017
- Published by Wolters Kluwer Health in Transplantation
- Vol. 101 (4) , 873-882
Prevalence and Clinical Impact of Donor-Specific Alloantibody Among Intestinal Transplant Recipients
Rejection remains the leading cause of allograft loss, and a major barrier to improving long-term outcomes after intestinal transplantation. Our aim is to define the prevalence and investigate the role of donor-specific antibody (DSA) on intestinal graft outcomes. The study includes 109 transplants performed in 95 recipients at a single center. Patients were screened for DSA pretransplant, monitored regularly posttransplant and when clinically indicated using the single-antigen bead Luminex assay. Standard induction immunosuppression was with interleukin-2 receptor antagonists, and antithymocyte globulin in high-risk recipients. Maintenance regimens were tacrolimus-based. Pretransplant DSA was detected in 12 (11%) recipients with 50% continuing to have circulating antibodies posttransplant. An additional 24 (25%) patients developed de novo DSA, and of these, 71% had persistent antibodies. Recipients with preformed DSA demonstrated elevated risks of early graft failure, whereas those with de novo DSA experienced accelerated graft loss once DSA was detected, reaching a 28% failure rate within 2 years. HLA-DQ mismatch is a significant risk factor for de novo DSA emergence, whereas the persistence of antibodies is predicted by DSA strength and specificity. Although inclusion of the liver in the intestinal allograft imparts an immunological advantage against rejection-related graft loss, this protective effect was lost among recipients with persistent DSA. The presence of DSA is associated with inferior graft outcomes among intestinal transplant recipients. An enhanced understanding of the mechanisms by which DSA causes allograft injury, and effective strategies targeting humoral immune reactivity are needed to improve long-term intestinal graft outcomes.
- 1 April 2017
- Published by Wolters Kluwer Health in Transplantation
- Vol. 101 (4) , 873-882
Prevalence and Clinical Impact of Donor-Specific Alloantibody Among Intestinal Transplant Recipients
Rejection remains the leading cause of allograft loss, and a major barrier to improving long-term outcomes after intestinal transplantation. Our aim is to define the prevalence and investigate the role of donor-specific antibody (DSA) on intestinal graft outcomes. The study includes 109 transplants performed in 95 recipients at a single center. Patients were screened for DSA pretransplant, monitored regularly posttransplant and when clinically indicated using the single-antigen bead Luminex assay. Standard induction immunosuppression was with interleukin-2 receptor antagonists, and antithymocyte globulin in high-risk recipients. Maintenance regimens were tacrolimus-based. Pretransplant DSA was detected in 12 (11%) recipients with 50% continuing to have circulating antibodies posttransplant. An additional 24 (25%) patients developed de novo DSA, and of these, 71% had persistent antibodies. Recipients with preformed DSA demonstrated elevated risks of early graft failure, whereas those with de novo DSA experienced accelerated graft loss once DSA was detected, reaching a 28% failure rate within 2 years. HLA-DQ mismatch is a significant risk factor for de novo DSA emergence, whereas the persistence of antibodies is predicted by DSA strength and specificity. Although inclusion of the liver in the intestinal allograft imparts an immunological advantage against rejection-related graft loss, this protective effect was lost among recipients with persistent DSA. The presence of DSA is associated with inferior graft outcomes among intestinal transplant recipients. An enhanced understanding of the mechanisms by which DSA causes allograft injury, and effective strategies targeting humoral immune reactivity are needed to improve long-term intestinal graft outcomes.
- 5 September 2016
- Published by Wiley in Pediatric Transplantation
- Vol. 21 (1)
Acute antibody‐mediated rejection inABO‐compatible pediatric liver transplant recipients: case series and review of the literature
AcuteAMRis well reported followingABO‐incompatibleLTx. However, it remains uncommon inABO‐compatibleLTx. It typically presents with graft dysfunction ≤2 weeks post‐LTx and is often associated with graft loss. We report the clinical presentation, treatment regimen, and outcome of six pediatricLTx recipients diagnosed with early acuteAMRbased on (i) clinical signs of graft dysfunction, (ii) histopathology indicative of acute injury ± C4d staining, and (iii) presence ofHLA DSA. All patients developed elevatedALTandGGT ≤ 45 days post‐LTx. All showedHLAclass I (n=4) and/orII(n=6)DSA(peakMFI6153–11 910). Four had de novoDSA, and two had preformedDSA. Five were initially diagnosed with ACR refractory to steroid therapy. Four exhibited resolution of graft dysfunction withAMRtherapy. Two had refractoryAMR—one was re‐transplanted; the other was treated with eculizumab and showed improvement in graft function but later died due to a tracheostomy complication. Our case series suggests thatAMRfollowingABO‐compatibleLTx may be under‐diagnosed. The presentation can be variable, and treatment should be individualized. Eculizumab may be an option for refractoryAMR. Ultimately, future multicenter studies are needed to better define diagnostic criteria, characterize optimal treatment, and assess long‐term outcomes following liverAMR.
- 5 September 2016
- Published by Wiley in Pediatric Transplantation
- Vol. 21 (1)
Acute antibody‐mediated rejection inABO‐compatible pediatric liver transplant recipients: case series and review of the literature
AcuteAMRis well reported followingABO‐incompatibleLTx. However, it remains uncommon inABO‐compatibleLTx. It typically presents with graft dysfunction ≤2 weeks post‐LTx and is often associated with graft loss. We report the clinical presentation, treatment regimen, and outcome of six pediatricLTx recipients diagnosed with early acuteAMRbased on (i) clinical signs of graft dysfunction, (ii) histopathology indicative of acute injury ± C4d staining, and (iii) presence ofHLA DSA. All patients developed elevatedALTandGGT ≤ 45 days post‐LTx. All showedHLAclass I (n=4) and/orII(n=6)DSA(peakMFI6153–11 910). Four had de novoDSA, and two had preformedDSA. Five were initially diagnosed with ACR refractory to steroid therapy. Four exhibited resolution of graft dysfunction withAMRtherapy. Two had refractoryAMR—one was re‐transplanted; the other was treated with eculizumab and showed improvement in graft function but later died due to a tracheostomy complication. Our case series suggests thatAMRfollowingABO‐compatibleLTx may be under‐diagnosed. The presentation can be variable, and treatment should be individualized. Eculizumab may be an option for refractoryAMR. Ultimately, future multicenter studies are needed to better define diagnostic criteria, characterize optimal treatment, and assess long‐term outcomes following liverAMR.
- Open Access
- 1 January 2016
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 3 (1) , e123
Intestinal Perforation Following Ileoscopy Through a Prolapsed Stoma in an Pediatric Intestinal Transplant Recipient With an Unrecognized Parastomal Hernia
Ileoscopy with mucosal biopsy is fundamental in the management and surveillance of inflammatory bowel disease patients and intestinal transplant recipients. There is a paucity of data describing the risks of ileoscopy in the presence of a prolapsed stoma. Parastomal hernias are frequently associated with prolapsed stomas. We report the first case of perforation during ileoscopy in the setting of a prolapsed stoma and unrecognized parastomal hernia. Recognition of parastomal hernia associated with stoma prolapse is of paramount importance in patients undergoing ileoscopy as it may increase the risk of perforation.
- 1 January 2016
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 3 (1) , e123
Open AccessIntestinal Perforation Following Ileoscopy Through a Prolapsed Stoma in an Pediatric Intestinal Transplant Recipient With an Unrecognized Parastomal Hernia
Ileoscopy with mucosal biopsy is fundamental in the management and surveillance of inflammatory bowel disease patients and intestinal transplant recipients. There is a paucity of data describing the risks of ileoscopy in the presence of a prolapsed stoma. Parastomal hernias are frequently associated with prolapsed stomas. We report the first case of perforation during ileoscopy in the setting of a prolapsed stoma and unrecognized parastomal hernia. Recognition of parastomal hernia associated with stoma prolapse is of paramount importance in patients undergoing ileoscopy as it may increase the risk of perforation.
- 1 December 2015
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 61 (6) , 636-640
Endoscopy Following Pediatric Intestinal Transplant
Objectives: Biopsies remain the criterion standard in the diagnosis of intestinal transplant (ITx) rejection, and gastrointestinal endoscopy plays a pivotal role in patient management. Herein, we describe a single‐center 23‐year endoscopic experience in pediatric ITx recipients.Methods: A retrospective review of endoscopy and pathology reports of all ITx recipients <18 years old transplanted between 1991 and 2013 was performed with the aim of describing the procedural indications, findings, and complications.Results: A total of 1770 endoscopic procedures within 1014 sessions were performed. A combination of esophagogastroduodenoscopy and ileoscopy was the most common procedure (36%). Increased stool output (35%) and surveillance endoscopy (32%) were the most common indications. A total of 162 episodes of biopsy‐proven rejection were diagnosed. The first episode of rejection occurred at a median of 1 month after ITx. Of histology‐proven rejections, 45% had normal‐appearing endoscopies. The rate of procedural complications, including but not limited to bleeding and perforation, was 1.8%.Conclusions: Endoscopy with biopsy plays a significant role in the care of ITx recipients. Multiple procedures are required for graft surveillance, diagnosis of rejection, subsequent treatment, and follow‐up of therapy. The gross endoscopic appearance, particularly in mild to moderate acute cellular rejection, does not correlate well with histology. Complex anatomy, complication rates that are higher than patients with non‐ITx pediatric endoscopy, and timely histologic interpretation by experienced pathologists are reasons that these procedures should be performed at centers accustomed to caring for ITx recipients. The field would benefit from the development of a noninvasive biomarker to reliably and efficiently detect rejection.
- 1 December 2015
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 61 (6) , 636-640
Endoscopy Following Pediatric Intestinal Transplant
Objectives: Biopsies remain the criterion standard in the diagnosis of intestinal transplant (ITx) rejection, and gastrointestinal endoscopy plays a pivotal role in patient management. Herein, we describe a single‐center 23‐year endoscopic experience in pediatric ITx recipients.Methods: A retrospective review of endoscopy and pathology reports of all ITx recipients <18 years old transplanted between 1991 and 2013 was performed with the aim of describing the procedural indications, findings, and complications.Results: A total of 1770 endoscopic procedures within 1014 sessions were performed. A combination of esophagogastroduodenoscopy and ileoscopy was the most common procedure (36%). Increased stool output (35%) and surveillance endoscopy (32%) were the most common indications. A total of 162 episodes of biopsy‐proven rejection were diagnosed. The first episode of rejection occurred at a median of 1 month after ITx. Of histology‐proven rejections, 45% had normal‐appearing endoscopies. The rate of procedural complications, including but not limited to bleeding and perforation, was 1.8%.Conclusions: Endoscopy with biopsy plays a significant role in the care of ITx recipients. Multiple procedures are required for graft surveillance, diagnosis of rejection, subsequent treatment, and follow‐up of therapy. The gross endoscopic appearance, particularly in mild to moderate acute cellular rejection, does not correlate well with histology. Complex anatomy, complication rates that are higher than patients with non‐ITx pediatric endoscopy, and timely histologic interpretation by experienced pathologists are reasons that these procedures should be performed at centers accustomed to caring for ITx recipients. The field would benefit from the development of a noninvasive biomarker to reliably and efficiently detect rejection.
- 1 July 2015
- Published by Wolters Kluwer Health in Transplantation
- Vol. 99 (7) , 1416-1422
Donor-specific HLA Antibodies Are Associated With Late Allograft Dysfunction After Pediatric Liver Transplantation
Background The role of donor-specific HLA antibodies (DSA) after pediatric liver transplantation (LTx) is not clearly established. We completed a cross-sectional study to characterize DSA in long-term survivors of pediatric LTx and assess the impact of C1q-binding DSA on allograft outcomes. Methods Serum samples were collected at routine clinic visits from 50 pediatric LTx recipients classified into 3 clinical phenotypes: nontolerant (n = 18) with de novo autoimmune hepatitis (DAIH) and/or late acute cellular rejection (ACR); stable (n = 25) on maintenance tacrolimus; operationally tolerant (n = 7). Samples were blinded, and antibody detection was performed using Luminex single antigen class I and II beads. Patients with positive DSA were tested for C1q-binding DSA. Results DSA were detected in 54% (n = 27) of the patients, with the majority directed at HLA class II antigens (DR, 41%; DQ, 53%). Patients with DSA were younger at the time of LTx (P = 0.016) and time of study (P = 0.024). Mean aspartate aminotransferase, alanine aminotransferase, total bilirubin, and gamma glutamyl transferase were higher in DSA-positive patients, though did not reach statistical significance. Nontolerant patients were significantly more likely to have DQ DSA (61%) compared to stable (20%) and tolerant (29%) patients (P = 0.021). The nontolerant phenotype was associated with DSA and C1q-binding DSA, with odds ratios of 13 (P = 0.015) and 8.6 (P = 0.006), respectively. The presence of DQ DSA was associated with DAIH and late ACR, with odds ratios of 12.5 (P = 0.004) and 10.8 (P = 0.006), respectively. Conclusions Allograft dysfunction is not always evident in patients with DSA, but DQ DSA are strongly associated with DAIH, late ACR, and chronic rejection.
- 1 July 2015
- Published by Wolters Kluwer Health in Transplantation
- Vol. 99 (7) , 1416-1422
Donor-specific HLA Antibodies Are Associated With Late Allograft Dysfunction After Pediatric Liver Transplantation
Background The role of donor-specific HLA antibodies (DSA) after pediatric liver transplantation (LTx) is not clearly established. We completed a cross-sectional study to characterize DSA in long-term survivors of pediatric LTx and assess the impact of C1q-binding DSA on allograft outcomes. Methods Serum samples were collected at routine clinic visits from 50 pediatric LTx recipients classified into 3 clinical phenotypes: nontolerant (n = 18) with de novo autoimmune hepatitis (DAIH) and/or late acute cellular rejection (ACR); stable (n = 25) on maintenance tacrolimus; operationally tolerant (n = 7). Samples were blinded, and antibody detection was performed using Luminex single antigen class I and II beads. Patients with positive DSA were tested for C1q-binding DSA. Results DSA were detected in 54% (n = 27) of the patients, with the majority directed at HLA class II antigens (DR, 41%; DQ, 53%). Patients with DSA were younger at the time of LTx (P = 0.016) and time of study (P = 0.024). Mean aspartate aminotransferase, alanine aminotransferase, total bilirubin, and gamma glutamyl transferase were higher in DSA-positive patients, though did not reach statistical significance. Nontolerant patients were significantly more likely to have DQ DSA (61%) compared to stable (20%) and tolerant (29%) patients (P = 0.021). The nontolerant phenotype was associated with DSA and C1q-binding DSA, with odds ratios of 13 (P = 0.015) and 8.6 (P = 0.006), respectively. The presence of DQ DSA was associated with DAIH and late ACR, with odds ratios of 12.5 (P = 0.004) and 10.8 (P = 0.006), respectively. Conclusions Allograft dysfunction is not always evident in patients with DSA, but DQ DSA are strongly associated with DAIH, late ACR, and chronic rejection.